Mercia EIS Funds

WEBINAR: The Native Antigen Company – Exit for Mercia EIS Fund

30th July, 2020

Mercia’s EIS fund principal Peter Dines discusses with Dr. Paul Mattick the recent sale of a portfolio company for 8x cost of investment.

The pair also discussed:

– The Mercia groups investment model
– Our EIS is a venture capital investment with downside protection
– This exit illustrates the potential when investing with Mercia

Loading...